Business Context and Reporting Period
This Form 8-K is a current report filed by resTORbio, Inc. (not Adicet Bio, Inc.) on August 15, 2018, regarding events occurring on August 14, 2018. The registrant is a Delaware corporation headquartered in Boston, MA, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Jeffrey Chodakewitz, M.D., to the Board of Directors, effective August 14, 2018. Dr. Chodakewitz was appointed as a Class III director, serving until the 2021 annual meeting of stockholders. He was also appointed to the compensation committee and the nominating and corporate governance committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the rationale for the director appointment, citing Dr. Chodakewitz's substantial experience in leading pharmaceutical companies. The company confirmed there are no undisclosed arrangements regarding his election and that he will receive standard cash and equity compensation for non-employee directors.
Investor Verification Checklist
- Verify the correct registrant name is resTORbio, Inc., not Adicet Bio, Inc.
- Confirm Dr. Chodakewitz's specific qualifications and prior leadership roles in the pharmaceutical industry.
- Review the attached press release (Exhibit 99.1) for additional context on the board expansion.
- Check subsequent filings for the impact of this appointment on board committee compositions.